CANNORDIC

MANUFACTURER OF TOMORROW'S MEDICAL TREATMENT

DENMARK

RESULTS

OF

Ongoing clinical trial

OF CANNASEN®CBD ARTHRITIS GEL

Lina Babickaite

Document made by
Medical & Research Manager: Lina Babickaite
E-mail: lb@cs-medica.com
Copenhagen: 2021-11-08

THE CLINICAL TRIAL PHASE III RESULTS

The CANNASEN®CBD Arthritis Gel (NGA-01) has, after conducting the final efficacy analysis in the ongoing Phase III trial, met all the trial's primary efficacy endpoints. The key results of the trial are summarized below:

Summary of the results

The primary objective of the clinical trial Phase III is to evaluate the efficacy of NGA-01 (CANNASEN®CBD Arthritis Gel) in the relief of joint pain, inflammation, and mobility for patients with Arthritis. The analysis is based on 28 cases of Osteoarthritis.

- The primary efficacy analysis of pain relief demonstrates NGA-01(CANNASEN®CBD Arthritis Gel) to be **89 percent** effective in the reduction of pain in joints in people with Osteoarthritis with joint pain in any of the joints; knee, hip, ankle, elbow, and shoulder. This was compared against placebo. Also, it was demonstrated that the product was **37,5 percent** effective in the reduction of pain in joints.
- The primary efficacy analysis of anti-inflammation demonstrates NGA-01(CANNASEN®CBD Arthritis Gel) to be **56 percent** effective in the reduction of swelling in joints versus placebo, and **27 percent** effective in the reduction of swelling in joints.
- The primary efficacy analysis of increased mobility demonstrates NGA-01(CANNASEN®CBD Arthritis Gel) to be **44 percent** effective in the reduction of stiffness in joints, **58 percent** effective in the reduction of crepitus in joints. This was compared against placebo. Furthermore, the product was shown to be **34 percent** effective in the reduction of stiffness in joints and **37 percent** effective in the reduction of crepitus in joints.
- The primary efficacy analysis of pain relief demonstrates NGA-01(CANNASEN®CBD Arthritis Gel) to be **63 percent** effective in the reduction of VAS score (from average 4,8 to average 1,8) versus placebo, and **30 percent** effective in the reduction of VAS score (from average 4,0 to average 2,8).
- **No adverse effect** was seen so far. The product was **well tolerated.**